AXSM News and Press, Axsome Therapeutics Inc. From 11/22/23

NEW YORK, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that it will host a virtual event on December 7 from 8 a.m. - 1...

NEW YORK, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, MD, Axsome’s Chief Executive Offi...

2023-11-20 00:24:09 ET Summary Biotech stocks have been heavily impacted by rising interest rates and the disruption caused by FTC-challenging acquisitions of biotechs. The equal-weight biotech ETF (XBI) has shown signs of a rebound after a prolonged downtrend, potentially due to ...

2023-11-11 06:50:00 ET You've probably heard all the old expressions about acting too quickly. "Haste makes waste" and "Look before you leap" are two that readily come to mind. However, there's also danger in waiting too long to make a decision -- especially when it comes to investing. ...

2023-11-09 10:23:00 ET Last year, the Federal Reserve began hiking interest rates in an effort to slow down the economy. Today, interest rates are at their highest levels since the early 2000s. For many businesses, an increase in interest rates has led to investors feeling less bullish on t...

2023-11-07 05:00:00 ET Summary Axsome's Q3 earnings show strong Auvelity sales but with significant SG&A cost increases and net loss expansion. Axsome's balance sheet is solid, with ample cash reserves and assets exceeding liabilities, suggesting a stable financial position. ...

2023-11-06 11:36:05 ET Axsome Therapeutics, Inc. (AXSM) Q3 2023 Earnings Conference Call November 06, 2023, 8:00 AM ET Company Participants Mark Jacobson - Chief Operating Officer Herriot Tabuteau - Chief Executive Officer Nick Pizzie - Chief Financial Officer ...

2023-11-06 07:02:58 ET More on Axsome Therapeutics Axsome Update: Buy At Dips And Hold Forever Axsome: Beyond The Numbers - Q2 Earnings Sparkle And A Pipeline Full Of Promise Mizuho says market fears for Harmony's Wakix drug are "overblown" Seeking Alpha ...

CGG ADR (CGGYY) is expected to report for quarter end 2023-09-30 ATI Physical Therapy Inc. Class A (ATIP) is expected to report $-4.08 for Q3 2023 Riot Platforms Inc. (RIOT) is expected to report $-0.29 for Q3 2023 Bain Capital Specialty Finance Inc. (BCSF) is expected to report $0.57...

Axsome Therapeutics Inc. (AXSM) is expected to report $-1.24 for Q3 2023